# EDGAR Filing Document

**Accession Number:** 0000353278
**File Stem:** 0001171843-26-000549
**Filing Date:** 2026-2
**Character Count:** 4314
**Document Hash:** 0adb32f074e574cf6af5805a0d7274e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-000549.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001171843-26-000549

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260131

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVO NORDISK A S
- **CENTRAL INDEX KEY:** 0000353278
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-82318
- **FILM NUMBER:** 26585582

**BUSINESS ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000
- **BUSINESS PHONE:** 4544448888

**MAIL ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO NORDISK A/S
- **DATE OF NAME CHANGE:** 19900807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO INDUSTRI A S /DENMARK/
- **DATE OF NAME CHANGE:** 19890811

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

***________________***

**FORM 6-K**

***________________***

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

January 31, 2026

***________________***

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé 1**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

***________________***

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

![](logo.jpg)

![](ca.jpg)

**New employee representative on the Board of Directors of Novo Nordisk A/S**

**Bagsværd, Denmark, 31 January 2026** – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore, he steps down from the Board of Directors and his alternate, Tanja Villumsen, joins the Board of Directors of Novo Nordisk A/S as employee representative with effect from today.

*Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.*

 

 

**Contacts for further information:**

---

| | |
|:---|:---|
| **Media:** |  |
| **Ambre James-Brown** | **Liz Skrbkova (US)** |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| **Investors:** |  |
| **Michael Novod** | **Jacob Martin Wiborg Rode** |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| **Max Ung** | **Sina Meyer** |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |

---

---

| | |
|:---|:---|
| **Alex Bruce** | **Christoffer Sho Togo Tullin** |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| **Frederik Taylor Pitter** |  |
| +1 609 613 0568 |  |
| fptr@novonordisk.com |  |

---

 

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br>Investor Relations | Novo Alle 1<br>2880 Bagsværd<br>Denmark | Telephone:<br>+45 4444 8888 | <br>www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  |  | Company announcement No 1 / 2026 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 2, 2026 NOVO NORDISK A/S <u>Maziar Mike Doustdar</u> Chief Executive Officer